Navigation Links
Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
Date:4/16/2012

CAMBRIDGE, Mass., April 17, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the approval of IB1001, an intravenous recombinant factor IX (rFIX) protein for the treatment and prevention of bleeding in individuals with hemophilia B. 

Based on the terms of its agreement with Ipsen (Euronext: IPN; ADR: IPSEY), Inspiration will receive a $35 million milestone payment associated with its filing of the BLA.  In return, Inspiration will issue a convertible note to Ipsen, bringing Ipsen's fully diluted equity ownership position in Inspiration to approximately 43.5%.

Approval of IB1001 would represent a significant advance for the hemophilia community, including the estimated 75% of people living with hemophilia worldwide who do not have adequate access to currently available treatments. IB1001 would be the first recombinant therapy for people with hemophilia B introduced in more than 15 years.

Regulatory review is now pending in both the U.S. and Europe. Inspiration's Marketing Authorization Application for IB1001 was accepted by the European Medicines Agency in September 2011.  The company is currently finalizing plans for additional regulatory filings and preparing for the commercial launch of IB1001.

"The introduction of recombinant factor IX was an important step forward in the treatment of hemophilia B, but a single product is not sufficient to meet the needs of all people affected by this disease," said John P. Butler, Inspiration's Chief Executive Officer. "At Inspiration, we are solely focused on the needs of people with hemophilia, and we are proud of the progress we have made towards bringing forward a new choice of treatment for patients. We plan to work closely with regulatory authorities both here in the U.S. and around the world to make IB1001 available as broadly and rapidly as
'/>"/>

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
2. Using magnetic toys as inspiration, researchers tease out structures of self-assembled clusters
3. Inspiration Biopharmaceuticals Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B
4. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
6. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
7. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
8. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
9. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
10. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
11. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... , July 3, 2015  Pomerantz LLP announces ... Puma Biotechnology, Inc. ("Puma" or the "Company")(NYSE: PBYI ... filed in United States District Court, Central District of ... is on behalf of a class consisting of all ... 23, 2014 and May 13, 2015 inclusive (the "Class ...
(Date:7/2/2015)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today announced a litigation update. ... Services Corp. et al. , Case No. 1:14-cv-00721-GBL-TCB, in ... of Virginia , the Court issued ... key claims in favor of the Defendants on the ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate two ... photon emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas ... brain scans and is believed to be the largest brain imaging study ever, will ...
(Date:7/1/2015)... Colo. and BANGALORE, India ... global genomic profiling company that uses next generation sequencing ... of Scott A. Storrer as chief executive ... CEO, he will be responsible for all strategy, business ... Chandru , who has served as Strand,s chairman and ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 2SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 3SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Puma Biotechnology, Inc. of Class Action Lawsuit and Upcoming Deadline - PBYI 4Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... to announce,that their new, unique immunoassay Rat/Mouse PINP- the ... I collagen levels in rodent,specimens*, is now available., ... to allow the,specific assessment of type I collagen levels ... the assessment of new osteoporosis drug candidates,in pre-clinical studies ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTAX: CTIC) ... e la Borsa ("CONSOB") granted authorization to,publish the ... by Article 8 and Article 56 of the ... common stock representing more than 10% of,the shares ...
... Dec. 2008, ATLANTA, Jan. 11 Cryolife, Inc., ... tissue has once again severely,maimed an elective knee surgery ... Shockingly the same deadly,organism that devastated Mr. Hohenbery took ... The Lykins, death, another of the Keenan Law ...
Cached Biology Technology:A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations. 2Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus 2Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus 3Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient 2
(Date:6/10/2015)... , June 10, 2015 ... "3D Sensor Market by Technology (Ultrasound, TOF, Structured ... (consumer Electronics, Entertainment, Automotive) and by Geography - ... by MarketsandMarkets, the market is expected to reach ... of 25.51% between 2015 and 2020. ...
(Date:6/9/2015)... , June 09, 2015 Research and ... of the "Gesture Recognition & Touchless Sensing ... Electronics, Automotive, & Others), Product (Biometric & Sanitary ... 2020" report to their offering. ... is expected to reach $ 23.55 Billion by ...
(Date:6/8/2015)... WASHINGTON , June 8, 2015  The ... announced today their selection of Troy Potter ... Chairman, effective immediately. SIBA is a non-profit association ... promote responsible policy, education and implementation of solutions ... public platforms. ...
Breaking Biology News(10 mins):3D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4Global Gesture Recognition & Touchless Sensing (Technology, Application & Products) Market 2015-2020 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 2Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 3Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 4Secure Identity & Biometrics Association (SIBA) Names Troy Potter of L-3 National Security Solutions as Chairman 5
... Washington D.C. Researchers at the U.S. Department ... today a major breakthrough in engineering systems of ... to important improvements across a range of industries, ... will use these new "RNA machines", to adjust ...
... - Drugs used to overcome cancer may also combat ... Wright, scientific director of the Michael G. DeGroote Institute ... study found that certain proteins, called kinases, that confer ... cancer," says Wright about the study published in Chemistry ...
... Albert Einstein College of Medicine of Yeshiva ... control the survival of messenger RNA ( mRNA ) arguably ... help regulate cell division and could therefore have implications for ... today,s online edition of the journal Cell . , ...
Cached Biology News:DOE researchers achieve important genetic breakthroughs to help develop cheaper biofuels 2Built-in 'self-destruct timer' causes ultimate death of messenger RNA in cells 2Built-in 'self-destruct timer' causes ultimate death of messenger RNA in cells 3
Mouse monoclonal [SPM302] to BCAR1, prediluted ( Abpromise for all tested applications). entrezGeneID: 9564 SwissProtID: P56945...
Phosphotyrosine IgG mouse monoclonal antibody: Alkaline Phosphatase conjugate...
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Mouse monoclonal [6E10] to LAP2 ( Abpromise for all tested applications). entrezGeneID: 7112 SwissProtID: P42166...
Biology Products: